APhA urges FDA to put patient safety first in review of peptide substances

WASHINGTON, July 17, 2026 /PRNewswire/ -- As the market for unregulated peptide products continues to grow, the American Pharmacists Association (APhA) is urging FDA and the Pharmacy Compounding Advisory Committee (PCAC) to prioritize patient safety, scientific evidence, and regulatory oversight as they evaluate several peptide substances nominated for inclusion on the Section 503A Bulks List.